Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052205 · ClinicalTrials.gov registry record · Phase 1
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1 study of Melanoma and Refractory Solid Tumors, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 12
- Study locations
NCT03052205: Completed Phase 1 study of Melanoma and Refractory Solid Tumors, sponsored by Idera Pharmaceuticals.
NCT03052205 is a Phase 1 study of Melanoma and Refractory Solid Tumors that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 54 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03052205, a Phase 1 study of Melanoma and Refractory Solid Tumors, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Conditions Studied
Interventions
- DRUG IMO-2125
Study Locations (12)
Other
- Rambam Medical Center - Haifa
- Hadassah Medical Center - Jerusalem
- Rabin Medical Center Beilinson Campus - Petah Tikva
- The Ella Lemelbaum Institute for Immuno-Oncology - Ramat Gan
Arizona
- Scottsdale Healthcare Hospitals DBA Honor Health - Scottsdale
- The University of Arizona Cancer Center - Tucson
Pennsylvania
- St. Luke's Hospital - Easton
- UPMC Hillman Cancer Center - Pittsburgh
California
- University of California San Francisco (UCSF) - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
Ohio
- The Cleveland Clinic Foundation - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-06-09 |
| Est. Completion | 2019-10-04 |
| Phase | Phase 1 |
What the finished NCT03052205 record still lists
NCT03052205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IMO-2125 is the first listed.
NCT03052205 lists 12 locations in 7 states (Other, Arizona, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT03052205 about?
NCT03052205 is a clinical study titled "A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors". This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
What is the current status of trial NCT03052205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-06-09. Estimated completion is 2019-10-04.
What conditions does trial NCT03052205 study?
This clinical trial studies the following conditions: Melanoma, Refractory Solid Tumors.
What interventions are being tested in trial NCT03052205?
The interventions under investigation include: IMO-2125 (DRUG).
Who is sponsoring clinical trial NCT03052205?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03052205 being conducted?
This trial has 12 study locations across Arizona, California, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03052205's enrollment target sits among peer trials
54 158th of 266 higher than 109 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI